[Autologous stem cell transplantation for soft tissue sarcoma]

IQWiG
Record ID 32010000662
English
Authors' recomendations: The evidence available at the time of publication of this report is not sufficient to deduce a possible additional benefit or a harm of autologous HSCT in soft tissue sarcomas. Thus, at present, there is neither proof nor indication of (additional) benefit or of harm from autologous HSCT in soft tissue sarcomas. At present, therefore, it does not appear justifiable to use autologous HSCT in patients with soft tissue sarcomas except in controlled clinical trials. The term "controlled clinical trials" includes non-randomized in addition to randomized controlled trials. However, adequate conditions are required to minimize bias in comparisons, for example, by reducing selection bias. In the interests of the patient, a major improvement is urgently needed in the quality of the data, including making publication of the results compulsory. If transplantation is to be used, the patient must be properly informed over the uncertain quality of the data.
Details
Project Status: Completed
Year Published: 2009
URL for additional information: http://www.iqwig.de/index.597.en.html
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Germany
MeSH Terms
  • Humans
  • Sarcoma
  • Soft Tissue Neoplasms
  • Stem Cell Transplantation
  • Transplantation, Autologous
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.